Cytomegalovirus infections are associated with severe morbidity and mortality is patients at
risk for disease because of immune system disabilities; in particular, recipients of stem cell …

Cytomegalovirus (CMV) is an opportunistic pathogen associated with significant morbidity
and mortality in immunocompromised hosts. Antiviral agents specifically targeting CMV were …

The recent approval of letermovir marks a new era of therapy for human cytomegalovirus
(HCMV) infections, particularly for the prevention of HCMV disease in hematopoietic stem …

Human cytomegalovirus remains an important pathogen for transplant recipients. To date, a
limited number of drugs have been licensed for the treatment of HCMV infection and …

Opinion statement In treating cytomegalovirus (CMV) infection, it is crucial to decide whether
one is treating pre-emptively or if one is treating established disease. Disease may be …

Background. Cytomegalovirus (CMV) infection causes morbidity in solid organ transplant
(SOT) recipients, either by direct injury or in association with chronic allograft rejection or …

Despite remarkable advances in the diagnostic and therapeutic modalities for its
management, cytomegalovirus (CMV) remains one of the most important pathogens …

We compared the efficacy and safety of valganciclovir with those of oral ganciclovir in
preventing cytomegalovirus (CMV) disease in high-risk seronegative solid organ transplant …

Cytomegalovirus (CMV) remains a cause of significant morbidity and mortality after
hematopoietic stem cell transplantation (HSCT). Ganciclovir prophylaxis, or preemptive …

Cytomegalovirus (CMV) continues to be one of the most important pathogens that
universally affect solid organ and allogeneic hematopoietic stem cell transplant recipients …